UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

August 08, 2017

Genomic analysis of cancer regulators. An in-depth genetic analysis of pancreatic cancer cells will be performed to help unravel the biological changes that lead to tumor growth, metastasis and treatment resistance. This genomic data will then be used to design new clinical trials that target the specific genes and cellular pathways that regulate cancer growth. Principal investigators are David Largaespada, Ph.D., of the University of Minnesota in Minneapolis; David Tuveson, M.D., Ph.D., of the University of Cambridge; and Christine Iacobuzio-Donahue, M.D., Ph.D., of Johns Hopkins University in Baltimore.

Targeting pancreatic cancer stem cells. Testing continues on experimental agents that can regulate a small subset of pancreatic cancer cells called stem cells, which are believed to be linked to many cases of inoperable pancreatic cancer. One promising agent is a genetically altered virus, called an adenovirus, designed to attack cancer cells while leaving healthy cells untouched. Principal investigators are David Curiel, M.D., Ph.D., of the UAB Comprehensive Cancer Center, and Masato Yamamoto, M.D., Ph.D. of the University of Minnesota in Minneapolis

In addition to these research projects, the SPORE grant supports a pancreatic cancer tissue resource center and a biostatistics program.

The NCI SPORE program started in 1992 as a way to promote interdisciplinary research and speed the transition of basic science findings to the clinical testing arena with the hope of reducing cancer-death rates and improving survival.

Source UAB Comprehensive Cancer Center